Pure Global AI
NCT05905458Not yet recruiting

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase II Study to Evaluate the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
Chengdu Suncadia Medicine Co., Ltd.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Hepatitis B
Drug/Device/Intervention
HRS9950 tablets
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chengdu Suncadia Medicine Co., Ltd.
Timeline & enrollment
Phase
Phase 2
Start date
Aug 01, 2023
End date
Jan 25, 2025
Enrollment
50 participants
Primary outcome

Change in mean log10 serum hepatitis B surface antigen levels from baseline to week 24

Summary

To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who
 are virologically suppressed on nucleoside or nucleotide analogues (NAs).

ICD-10 classifications
Acute hepatitis BChronic viral hepatitis B without delta-agentAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agent : other and unspecified phaseChronic viral hepatitis B without delta-agent : immune-tolerant phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05905458
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05905458 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chengdu Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.